Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2018-12-10 Capital/Financing Update
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 6, 2018. It reports the entry into a material definitive agreement, specifically an amendment to a loan and security agreement that refinances and extends a credit facility. The content focuses on financing activities, including loan terms, interest rates, and fees. There are no financial statements or comprehensive financial performance data presented, nor is this an earnings release or annual/interim report. The document is not a report publication announcement but a current report on a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2018-12-10 English
PRIMARY DOCUMENT
Director's Dealing
2018-12-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 3, 2018. It reports "Other Events" specifically a press release announcing long-term clinical data from a Phase I/II trial and confirming a dose for a pivotal study. The document is short (3624 characters) and primarily serves as a current report to announce this event. It does not contain detailed financial statements or comprehensive financial data. The nature of the content is an announcement of clinical trial data and dose confirmation, which is typical for an 8-K current report. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes SEC Form 8-K filings reporting events or press releases.
2018-12-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about pipeline expansion and technology advancements at a Research & Development Day, which is an event update rather than a full financial report or earnings release. The document length is 3035 characters, relatively short, and it mainly references a press release as an exhibit. There are no detailed financial statements or comprehensive data typical of Annual Reports (10-K), Interim Reports (IR), or Earnings Releases (ER). It is not a certification or officer attestation, so it is not Regulatory Filings (RNS). The content fits best as a general regulatory announcement of a corporate event or update, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other categories.
2018-11-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (a lease amendment) and a press release about clinical study data. There are no financial statements or detailed financial results presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory announcement of material events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5870 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content.
2018-11-15 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2018. It announces the issuance of a press release regarding financial results for the quarter ended September 30, 2018. The document itself does not contain the financial results but references an attached press release (Exhibit 99.1) that announces these results. The length of the document is 3764 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, since this document is short and primarily announces the release of financial results without containing substantive financial data itself, it should be classified as an Earnings Release (ER). The document is not a full quarterly report (IR) because it lacks detailed financial statements or analysis, only announcing the results. Therefore, the best classification is Earnings Release (ER) with high confidence.
2018-11-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.